PharmaPre-market
NCLAT rules CCI can't examine patent disputes
pre-market1 source ↓written by the desknot a recommendation
The NCLAT has ruled that the Competition Commission of India lacks authority to investigate disputes over patents, specifically dismissing a complaint against Vifor International regarding its patent for Ferric Carboxymaltose injection. This decision emphasizes that the Patent Act supersedes the Competition Act in such cases, impacting regulatory oversight in the pharmaceutical sector.
This ruling may influence future patent-related disputes and regulatory approaches within the Pharma sector. 📉
Not investment advice. For informational purposes only.